According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical trial. This clinical trial will be testing the company’s investigational product candidate CRN01941 which is being developed as a treatment for neuroendocrine tumors. Crinetics is focused on the development of treatments for rare endocrine diseases and endocrine tumors.
About Neuroendocrine Tumors
Neuroendocrine tumors are atypical growths of tissue that usually originate in the cells of either the nervous system or the endocrine system, the latter of which plays a major role in the circulation of various hormones. While many of these tumors are benign, some may become cancerous. The cause of these tumors is not understood, but there appearance can be a part of a number of heritable conditions, such as tuberous sclerosis and neurofibromatosis. They most commonly appear in the intestine, pancreas, or lungs. Despite the many different variants of neuroendocrine tumors, they share a similar appearance, produce biogenic amines and hormones, and have secretory granules. These tumors do not have universal symptoms and they generally vary depending on where they appear. There are variety of therapies that may be attempted to treat neuroendocrine tumors. These include surgery, chemotherapy, certain targeted therapies, radionuclide therapy, and cryoablation, just to name a few. To learn more about neuroendocrine tumors, click here.
About The Clinical Trial
CRN01941 is designated as a nonpeptide somatostatin receptor subtype 2 biased agonist and is intended as an orally administered therapy for patients with these tumors. This early stage trial will test the drug on 119 healthy subjects. The intent of most Phase 1 studies is not to evaluate the efficacy of the drug but to measure other aspects of the therapy, such as safety, tolerability, and pharmacokinetics. This critical information will allow researchers to get a better understanding of how the drug will behave when it is introduced to the intended patient population. The trial will evaluate both single and multiple doses.
